Lipocine Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $11.2M | $-2.9M | $500.0K | $16.1M | $0 | $165.0K | $428.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $8.6M | $7.4M | $10.2M | $8.6M | $7.7M | $9.7M | $7.5M | $6.5M |
| SG&A Expense | $3.8M | $5.0M | $4.9M | $4.1M | $5.3M | $8.2M | $5.6M | $5.3M |
| Operating Income | $-10.4M | $-1.2M | $-17.9M | $-12.1M | $3.1M | $-18.0M | $-12.9M | $-11.3M |
| Operating Margin | -524.7% | -10.3% | 629.0% | -2,423.9% | 19.5% | — | -7,818.8% | -2,646.0% |
| Interest Expense | — | — | — | $27.1K | $203.3K | $386.6K | $766.7K | — |
| Pretax Income | $-9.6M | $9.0K | $-16.4M | $-10.8M | $-634.2K | $-21.0M | $-13.0M | $-11.7M |
| Income Tax Expense | $200 | $681 | $755 | $681 | $200 | $200 | $200 | $700 |
| Net Income | $-9.6M | $8.4K | $-16.4M | $-10.8M | $-634.4K | $-21.0M | $-13.0M | $-11.7M |
| Net Margin | -487.1% | 0.1% | 573.6% | -2,151.7% | -3.9% | — | -7,883.7% | -2,724.1% |
| EPS (Basic) | $-1.77 | — | $-3.10 | $-2.06 | $-0.01 | $-0.38 | $-0.25 | $-0.28 |
| EPS (Diluted) | $-1.69 | — | $-3.14 | $-2.15 | $-0.01 | $-0.38 | $-0.25 | $-0.28 |
| Shares Outstanding (Basic) | 5.4M | 5.3M | 5.3M | 5.2M | 86.9M | 55.7M | 51.8M | 42.7M |
| Shares Outstanding (Diluted) | 5.7M | 5.4M | 5.3M | 5.3M | 87.6M | 55.7M | 51.8M | 42.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |